| ZFIN ID: ZDB-EXP-210729-3 |
Experiment Conditions Description: chemical treatment by environment: acetylsalicylic acid, chemical treatment by environment: ponatinib
| chemical treatment by environment: acetylsalicylic acid |
|---|
| Name: | chemical treatment by environment |
|---|---|
| Synonyms: | |
| Definition: | Chemical treatment condition in which the chemical is introduced through the environment. For zebrafish this is the tank water. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000238] |
| Name: | acetylsalicylic acid |
|---|---|
| Synonyms: | 2-(ACETYLOXY)BENZOIC ACID, 2-Acetoxybenzenecarboxylic acid, 2-acetoxybenzoic acid, Acetylsalicylate, Acetylsalicylic acid, Acetylsalicylsaeure, acide 2-(acetyloxy)benzoique, acide acetylsalicylique, acido acetilsalicilico, acidum acetylsalicylicum, ASA, Aspirin, Azetylsalizylsaeure, Easprin, o-acetoxybenzoic acid, O-acetylsalicylic acid, o-carboxyphenyl acetate, salicylic acid acetate |
| Definition: | A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity. |
| Ontology: | ChEBI [CHEBI:15365] ( EBI ) |
| chemical treatment by environment: ponatinib |
|---|
| Name: | chemical treatment by environment |
|---|---|
| Synonyms: | |
| Definition: | Chemical treatment condition in which the chemical is introduced through the environment. For zebrafish this is the tank water. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000238] |
| Name: | ponatinib |
|---|---|
| Synonyms: | 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide, AP 24534, AP-24534, AP24534, ponatinib, ponatinibum |
| Definition: | A benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzoic acid with the anilino group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABL(T315I). |
| Ontology: | ChEBI [CHEBI:78543] ( EBI ) |
| Publication: | Zhu et al., 2020 |
|---|